[BostonCard]

https://academic.oup.com/jid/advance-art...28/5826985

It looks like plasma from patients who recover from COVID-19 can help stop viral shedding, but doesn't seem to prevent death from COVID-19 complications in critically ill patients.  Probably because at that point, the damage is not being done by the virus, but by an overactive immune response.

Earlier administration might help, but it is hard to figure out early in the course who will become critically ill and who will have a mild course.

BC

[BostonCard]

https://academic.oup.com/jid/advance-art...28/5826985

It looks like plasma from patients who recover from COVID-19 can help stop viral shedding, but doesn't seem to prevent death from COVID-19 complications in critically ill patients.  Probably because at that point, the damage is not being done by the virus, but by an overactive immune response.

Earlier administration might help, but it is hard to figure out early in the course who will become critically ill and who will have a mild course.

BC

[OutsiderFan]

https://academic.oup.com/jid/advance-art...28/5826985

It looks like plasma from patients who recover from COVID-19 can help stop viral shedding, but doesn't seem to prevent death from COVID-19 complications in critically ill patients.  Probably because at that point, the damage is not being done by the virus, but by an overactive immune response.

Earlier administration might help, but it is hard to figure out early in the course who will become critically ill and who will have a mild course.

BC

This is the same dilemma that would happen with Remdesivir and other drugs.  They only work if used on early disease development. We don't know who is going to develop symptoms on which it will work, or if it will work on those selected to get it.

[OutsiderFan]

https://academic.oup.com/jid/advance-art...28/5826985

It looks like plasma from patients who recover from COVID-19 can help stop viral shedding, but doesn't seem to prevent death from COVID-19 complications in critically ill patients.  Probably because at that point, the damage is not being done by the virus, but by an overactive immune response.

Earlier administration might help, but it is hard to figure out early in the course who will become critically ill and who will have a mild course.

BC

This is the same dilemma that would happen with Remdesivir and other drugs.  They only work if used on early disease development. We don't know who is going to develop symptoms on which it will work, or if it will work on those selected to get it.

[BostonCard]

The difference is that remdisivir production can be scaled up, and you can imagine a situation where upon diagnosis everyone gets set up with remdisivir infusions.

Convalescent plasma is much harder to come by.

BC

[BostonCard]

The difference is that remdisivir production can be scaled up, and you can imagine a situation where upon diagnosis everyone gets set up with remdisivir infusions.

Convalescent plasma is much harder to come by.

BC

[Goose]

Not really new news, but it certainly looks like this approach hasn't worked well in really sick patients.
https://www.medpagetoday.org/infectiousd...on&vpass=1

[Goose]

Not really new news, but it certainly looks like this approach hasn't worked well in really sick patients.
https://www.medpagetoday.org/infectiousd...on&vpass=1